Compare Guardant Health Inc. Common Stock (GH) vs Rambus Inc. Common Stock (RMBS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Guardant Health Inc. Common Stock vs Rambus Inc. Common Stock — how do they compare? Guardant Health Inc. Common Stock trades at $163.01 (market cap $21.74B), while Rambus Inc. Common Stock trades at $89.45 (market cap $10.66B). The key difference: Guardant Health Inc. Common Stock is far larger — about 2× Rambus Inc. Common Stock's market cap, and Guardant Health Inc. Common Stock is trading nearer its 52-week high, Rambus Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Guardant Health Inc. Common Stock for 3 Days and Rambus Inc. Common Stock for 0 Days on average.
| GH | RMBS | |
|---|---|---|
Market Cap | $21.74B | $10.66B |
Volume | 1,297,295 | 2,136,075 |
Sector | Health | Technology |
52-Week High | $187.22 | $170.66 |
52-Week Low | $64.19 | $79.73 |
Typical Hold Time | 3 Days | 0 Days |
Enterprise Value | $22.38B | $9.85B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Guardant Health (GH) trades at $162.09, down 0.43% today, with a bearish technical signal despite strong analyst support. The company shows robust revenue growth to $982M in 2025 but remains unprofitable with a -38.33% net margin. Recent FDA and European approvals for cancer diagnostics and expanded insurance coverage provide significant growth catalysts.
Investment outlook balances high growth potential against persistent losses. Analyst consensus is strongly bullish with a $202.40 price target (25% upside), but investors face execution risk as the company burns cash and misses earnings estimates. The stock offers substantial upside if Guardant can achieve profitability through its expanding product portfolio.
Rambus (RMBS) trades at $98.17, down 2.84% over 24 hours, with a neutral technical signal and key support at $96. The company reported strong profitability with a 31.69% net income margin and beat EPS estimates in two of the last three quarters. Recent news highlights its focus on AI infrastructure with new product launches, positioning it to benefit from growing demand for high-speed memory solutions.
The outlook is positive given analyst consensus of a $161.75 price target and 78.57% buy ratings, but risks include high valuation multiples and competitive pressures. Execution on AI-driven growth and maintaining earnings momentum are critical for stock appreciation, while any miss in upcoming results could pressure the premium valuation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Guardant Health Inc. Common Stock
Guardant Health develops blood tests for cancer care. Its tests support genomic profiling, cancer screening, recurrence monitoring, and treatment decisions.
Read more on GH →About Rambus Inc. Common Stock
Rambus Inc. is a semiconductor and silicon IP company that licenses chip interface and security technologies, including memory interface chipsets for DDR5 and DDR4 server and client DIMMs, interface IP for PCIe, CXL, and HBM, and security IP such as Root of Trust and memory encryption. It serves data center, AI, automotive, and IoT markets.
Read more on RMBS →
